Filing Flows › Vivos Therapeutics (VVOS) › Guidance & outlook
Vivos Therapeutics (VVOS) guidance and outlook
Vivos Therapeutics (VVOS) gave its guidance on Oct 19, 2026: Revenue (segment) +20% for .
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | +20% | new |
From the earnings release filed Oct 19, 2026 (8-K on EDGAR).
Vivos Therapeutics' latest quarter
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Questions
Did Vivos Therapeutics raise or lower its guidance?
Vivos Therapeutics (VVOS) gave its guidance on Oct 19, 2026: Revenue (segment) +20% for .
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.